Log in or Sign up for Free to view tailored content for your specialty!
Ocular Oncology News
T-cell redirection therapy shows durable response for metastatic uveal melanoma
Immunocore Limited presented data from the IMCgp100-102 trial at the American Society of Clinical Oncology meeting that showed a durable response and strong overall survival rate in patients with metastatic uveal melanoma.
VIDEO: IMCgp100 a promising option for uveal melanoma treatment, speaker says
HONOLULU — Early studies have shown IMCgp100 (Immunocore), a bispecific T-cell redirector, to be “extremely promising” for the treatment of uveal melanoma, Richard Carvajal, MD, said at the Association for Research in Vision and Ophthalmology meeting here.
Log in or Sign up for Free to view tailored content for your specialty!
Ocular surface squamous neoplasia seen in congenital ichthyosis
Ocular surface squamous neoplasia, or OSSN, is seen often as an abnormal growth in the ocular surface predominantly near the limbus. Immunosuppression and ultraviolet light exposure are known high risk factors for developing OSSN. DNA repair defects such as xeroderma pigmentosum have been reported to develop skin carcinomas. Similarly, OSSN is known to happen in xeroderma pigmentosum patients. There are few dermatological conditions in which OSSN is often noted. We report here a case of giant invasive OSSN in a patient with congenital ichthyosis.
Multimodal imaging can detect 'ghost' tumors
PHILADELPHIA — Multimodal imaging can assist in detecting intraocular tumors that cannot be seen with ophthalmoscopy, according to a speaker at the Wills Eye Conference.
Jerry A. Shields receives first Brady-Shields Endowed Chair in Ocular Oncology
PHILADELPHIA — Wills Eye Hospital presented the Brady-Shields Endowed Chair in Ocular Oncology to inaugural recipient Jerry A. Shields, MD, co-founder and director emeritus of the Ocular Oncology Service at Wills Eye Hospital.
Aura Biosciences closes $30 million in Series C funding
Aura Biosciences has completed $30 million in Series C financing, according to a company press release.
VIDEO: Aura hopes to bring first ocular melanoma treatment to fruition
NEW ORLEANS ― At the Ophthalmology Innovation Summit here, Elisabet de los Pinos, PhD, CEO of Aura Biosciences, discusses the work the company is doing to bring its treatment for ocular melanoma using viral nanoparticle conjugates to the U.S.
Light-activated viral nanoparticle for treatment of choroidal melanoma meets early study endpoints
NEW ORLEANS — Choroidal melanoma has a high unmet medical need, according to Carol L. Shields, MD, and results of an early-stage study of a light-activated viral nanoparticle lend encouragement that a therapy may be developed to meet that need.
Uveal melanoma prognoses vary depending on genomic subset
Four molecularly distinct subtypes of uveal melanomas have been identified, two with poorer prognosis and two with better prognosis, according to a study.
Ophthalmic diffuse large B-cell lymphoma survival affected by different factors
Several factors, including increased age and location, can influence overall survival rates in patients with ophthalmic diffuse large B-cell lymphoma, according to a study.
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read